{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:30:48Z","timestamp":1790926248573,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,30]],"date-time":"2009-08-30T00:00:00Z","timestamp":1251590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s11914-009-0015-2","type":"journal-article","created":{"date-parts":[[2009,8,29]],"date-time":"2009-08-29T02:00:27Z","timestamp":1251511227000},"page":"91-95","source":"Crossref","is-referenced-by-count":8,"title":["New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab"],"prefix":"10.1007","volume":"7","author":[{"given":"Stuart L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,30]]},"reference":[{"key":"15_CR1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"D.M. Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809\u20131822.","journal-title":"N Engl J Med"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"K.W. Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, et al.: HORIZON Recurrent Fracture Trial: Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1799\u20131809.","journal-title":"N Engl J Med"},{"key":"15_CR3","unstructured":"Zoledronic acid prescribing information. Available at http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/reclast.pdf . Accessed June 5, 2009."},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M. McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, et al.: Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122\u2013128.","journal-title":"Bone"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"D.M. Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 2009, 373:1253\u20131263.","journal-title":"Lancet"},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","volume":"105","author":"S. Ronkin","year":"2005","unstructured":"Ronkin S, Northington R, Baracat E, et al.: Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator in postmenopausal women. Obstet Gynecol 2005, 105:1397\u20131404.","journal-title":"Obstet Gynecol"},{"issue":"Suppl1","key":"15_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.fertnstert.2006.07.236","volume":"XX","author":"D. Duren Van","year":"2006","unstructured":"Van Duren D, Ronkin S, Pickar J, et al.: Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstract]. Fertil Steril 2006, XX(Suppl 1):S88\u2013S89.","journal-title":"Fertil Steril"},{"key":"15_CR8","first-page":"P79","volume":"23","author":"I. Itabashi","year":"2008","unstructured":"Itabashi I, Ohta H, Ebede B, et al.: A double-blind, placebocontrolled, dose-response study of bazedoxifene in Japanese postmenopausal women with osteoporosis [abstract]. J Bone Miner Res 2008, 23:P79.","journal-title":"J Bone Miner Res"},{"key":"15_CR9","first-page":"1212","volume":"15","author":"G. Bachmann","year":"2008","unstructured":"Bachmann G, Crosby U, Feldman RA, et al.: Vasomotor effects of bazedoxifene in non-flushing postmenopausal women [abstract P-10]. Menopause 2008, 15:1212.","journal-title":"Menopause"},{"key":"15_CR10","first-page":"4","volume":"14","author":"P. Boudes","year":"2003","unstructured":"Boudes P, Ronkin S, Korner P, et al.: Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain [abstract]. Osteoporos Int 2003, 14:S4.","journal-title":"Osteoporos Int"},{"key":"15_CR11","first-page":"W387","volume":"22","author":"C.H. Chestnut","year":"2007","unstructured":"Chestnut CH, Christiansen C, Hoeck HC, et al.: Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis [abstract]. J Bone Miner Res 2007, 22:W387.","journal-title":"J Bone Miner Res"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1359\/jbmr.070402","volume":"22","author":"C.P. Miller","year":"2007","unstructured":"Miller CP, Christiansen C, Hoeck HC, et al.: Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis. Results of a 2-year, phase III, placebo and active-controlled study [abstract]. J Bone Miner Res 2007, 22:1209.","journal-title":"J Bone Miner Res"},{"key":"15_CR13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","volume":"23","author":"P.D. Miller","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C, et al.: Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008, 23:525\u2013535.","journal-title":"J Bone Miner Res"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"S.L. Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, et al.: Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923\u20131934.","journal-title":"J Bone Miner Res"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"W385","DOI":"10.1359\/jbmr.061116","volume":"22","author":"J.D. Adachi","year":"2007","unstructured":"Adachi JD, Chesnut CH, Brown JP, et al.: Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial [abstract]. J Bone Miner Res 2007, 22:W385.","journal-title":"J Bone Miner Res"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"P.D. Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222\u2013229.","journal-title":"Bone"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"P.J. Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, et al.: Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059\u20131066.","journal-title":"J Bone Miner Res"},{"key":"15_CR18","unstructured":"Cummings SR, McClung MR, Christiansen C, et al.: A phase III study of the effects of denosumab on vertebral, non-vertebral, and hip fractures: results from the freedom trial. J Bone Miner Res 2009 (in press)."},{"key":"15_CR19","unstructured":"Miller P: Denosumab. Curr Osteoporosis Reports 2009 (in press)."}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-009-0015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-009-0015-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-009-0015-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:33:44Z","timestamp":1559435624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-009-0015-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,30]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11914-009-0015-2","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,30]]}}}